Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab Prophylaxis in Hemophilia A Patients Undergoing Minor Surgery
NCT03361137Phase 4Terminated
- Sponsor
- Genentech
- Start
- Jun 2018
- Primary completion
- Mar 2020
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of emicizumab in hemophilia A (5 arms), sponsored by Genentech. Primary endpoints: Percentage of Participants Without Excessive Bleeding at Surgical Sites and Did Not Require BPA/FVIII Use at 48 hours, Percentage of Participants With Excessive Bleeding at Surgical Sites and Required BPA/FVIII Use at 48 hours and 5 more. Started Jun 2018; status: terminated.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT03361137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03361137.